<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34520757</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN><JournalIssue CitedMedium="Internet"><Volume>297</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>AAA+ ATPase p97/VCP mutants and inhibitor binding disrupt inter-domain coupling and subsequent allosteric activation.</ArticleTitle><Pagination><StartPage>101187</StartPage><MedlinePgn>101187</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101187</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbc.2021.101187</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0021-9258(21)00989-3</ELocationID><Abstract><AbstractText>The human AAA+ ATPase p97, also known as valosin-containing protein, a potential target for cancer therapeutics, plays a vital role in the clearing of misfolded proteins. p97 dysfunction is also known to play a crucial role in several neurodegenerative disorders, such as MultiSystem Proteinopathy 1 (MSP-1) and Familial Amyotrophic Lateral Sclerosis (ALS). However, the structural basis of its role in such diseases remains elusive. Here, we present cryo-EM structural analyses of four disease mutants p97<sup>R155H</sup>, p97<sup>R191Q</sup>, p97<sup>A232E</sup>, p97<sup>D592N</sup>, as well as p97<sup>E470D</sup>, implicated in resistance to the drug CB-5083, a potent p97 inhibitor. Our cryo-EM structures demonstrate that these mutations affect nucleotide-driven allosteric activation across the three principal p97 domains (N, D1, and D2) by predominantly interfering with either (1) the coupling between the D1 and N-terminal domains (p97<sup>R155H</sup> and p97<sup>R191Q</sup>), (2) the interprotomer interactions (p97<sup>A232E</sup>), or (3) the coupling between D1 and D2 nucleotide domains (p97<sup>D592N</sup>, p97<sup>E470D</sup>). We also show that binding of the competitive inhibitor, CB-5083, to the D2 domain prevents conformational changes similar to those seen for mutations that affect coupling between the D1 and D2 domains. Our studies enable tracing of the path of allosteric activation across p97 and establish a common mechanistic link between active site inhibition and defects in allosteric activation by disease-causing mutations and have potential implications for the design of novel allosteric compounds that can modulate p97 function.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caffrey</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berezuk</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuttle</LastName><ForeName>Katharine</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chittori</LastName><ForeName>Sagar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subramaniam</LastName><ForeName>Sriram</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address: sriram.subramaniam@ubc.ca.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U24 GM129547</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.6.4.6</RegistryNumber><NameOfSubstance UI="C000614178">VCP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.6</RegistryNumber><NameOfSubstance UI="D000074405">Valosin Containing Protein</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C531617">Amyotrophic lateral sclerosis 1</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000494" MajorTopicYN="N">Allosteric Regulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019943" MajorTopicYN="N">Amino Acid Substitution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020285" MajorTopicYN="N">Cryoelectron Microscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020125" MajorTopicYN="Y">Mutation, Missense</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072417" MajorTopicYN="N">Protein Domains</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000074405" MajorTopicYN="N">Valosin Containing Protein</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AAA+ ATPase</Keyword><Keyword MajorTopicYN="N">CB-5083</Keyword><Keyword MajorTopicYN="N">Protein Degradation</Keyword><Keyword MajorTopicYN="N">Protein Quality Control</Keyword><Keyword MajorTopicYN="N">VCP</Keyword><Keyword MajorTopicYN="N">p97</Keyword><Keyword MajorTopicYN="N">p97 mutants</Keyword></KeywordList><CoiStatement>Conflict of interest S. S. is Founder and CEO of Gandeeva Therapeutics Inc, a drug discovery company based in Vancouver. All other authors declare that they have no conflicts of interest with the contents of this article.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>14</Day><Hour>20</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34520757</ArticleId><ArticleId IdType="pmc">PMC8517850</ArticleId><ArticleId IdType="doi">10.1016/j.jbc.2021.101187</ArticleId><ArticleId IdType="pii">S0021-9258(21)00989-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Erzberger J.P., Berger J.M. Evolutionary relationships and structural mechanisms of AAA+ proteins. Annu. Rev. Biophys. Biomol. Struct. 2006;35:93&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pubmed">16689629</ArticleId></ArticleIdList></Reference><Reference><Citation>Stach L., Freemont P.S. The AAA+ ATPase p97, a cellular multitool. Biochem. J. 2017;474:2953&#x2013;2976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5559722</ArticleId><ArticleId IdType="pubmed">28819009</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooney I., Han H., Stewart M.G., Carson R.H., Hansen D.T., Iwasa J.H., Price J.C., Hill C.P., Shen P.S. Structure of the Cdc48 segregase in the act of unfolding an authentic substrate. Science. 2019;365:502&#x2013;505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7362759</ArticleId><ArticleId IdType="pubmed">31249134</ArticleId></ArticleIdList></Reference><Reference><Citation>Twomey E.C., Ji Z., Wales T.E., Bodnar N.O., Ficarro S.B., Marto J.A., Engen J.R., Rapoport T.A. Substrate processing by the Cdc48 ATPase complex is initiated by ubiquitin unfolding. Science. 2019;365</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6980381</ArticleId><ArticleId IdType="pubmed">31249135</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee S., Bartesaghi A., Merk A., Rao P., Bulfer S.L., Yan Y., Green N., Mroczkowski B., Neitz R.J., Wipf P., Falconieri V., Deshaies R.J., Milne J.L.S., Huryn D., Arkin M. 2.3 &#xc5; resolution cryo-EM structure of human p97 and mechanism of allosteric inhibition. Science. 2016;351:871&#x2013;875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6946184</ArticleId><ArticleId IdType="pubmed">26822609</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulfer S.L., Chou T.F., Arkin M.R. P97 disease mutations modulate nucleotide-induced conformation to alter protein-protein interactions. ACS Chem. Biol. 2016;11:2112&#x2013;2116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5224236</ArticleId><ArticleId IdType="pubmed">27267671</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshaies R.J. Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy. BMC Biol. 2014;12:94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4226866</ArticleId><ArticleId IdType="pubmed">25385277</ArticleId></ArticleIdList></Reference><Reference><Citation>Roux B., Vaganay C., Vargas J.D., Alexe G., Benaksas C., Pardieu B., Fenouille N., Ellegast J.M., Malolepsza E., Ling F., Sodaro G., Ross L., Pikman Y., Conway A.S., Tang Y. Targeting acute myeloid leukemia dependency on VCP-mediated DNA repair through a selective second-generation small-molecule inhibitor. Sci. Transl. Med. 2021;13</Citation><ArticleIdList><ArticleId IdType="pubmed">33790022</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Wakita T., Shimizu H. Valosin-Containing protein (VCP/p97) is required for poliovirus replication and is involved in cellular protein secretion pathway in poliovirus infection. J.&#xa0;Virol. 2012;86:5541&#x2013;5553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3347272</ArticleId><ArticleId IdType="pubmed">22379090</ArticleId></ArticleIdList></Reference><Reference><Citation>Huryn D.M., Kornfilt D.J.P., Wipf P. P97: An emerging target for cancer, neurodegenerative diseases, and viral infections. J.&#xa0;Med. Chem. 2020;63:1892&#x2013;1907.</Citation><ArticleIdList><ArticleId IdType="pubmed">31550150</ArticleId></ArticleIdList></Reference><Reference><Citation>Watts G.D.J., Wymer J., Kovach M.J., Mehta S.G., Mumm S., Darvish D., Pestronk A., Whyte M.P., Kimonis V.E. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein. Nat. Genet. 2004;36:377&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pubmed">15034582</ArticleId></ArticleIdList></Reference><Reference><Citation>Niwa H., Ewens C.A., Tsang C., Yeung H.O., Zhang X., Freemont P.S. The role of the N-domain in the atpase activity of the mammalian AAA ATPase p97/VCP. J.&#xa0;Biol. Chem. 2012;287:8561&#x2013;8570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3318706</ArticleId><ArticleId IdType="pubmed">22270372</ArticleId></ArticleIdList></Reference><Reference><Citation>Blythe E.E., Gates S.N., Deshaies R.J., Martin A. Multisystem proteinopathy mutations in VCP/p97 increase NPLOC4&#xb7;UFD1L binding and substrate processing. Structure. 2019;27:1820&#x2013;1829.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6929323</ArticleId><ArticleId IdType="pubmed">31623962</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson J.O., Mandrioli J., Benatar M., Abramzon Y., Van Deerlin V.M., Trojanowski J.Q., Gibbs J.R., Brunetti M., Gronka S., Wuu J., Ding J., McCluskey L., Martinez-Lage M., Falcone D., Hernandez D.G. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron. 2010;68:857&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3032425</ArticleId><ArticleId IdType="pubmed">21145000</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastola P., Wang F., Schaich M.A., Gan T., Freudenthal B.D., Chou T.F., Chien J. Specific mutations in the D1&#x2013;D2 linker region of VCP/p97 enhance ATPase activity and confer resistance to VCP inhibitors. Cell Death Discov. 2017;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5672561</ArticleId><ArticleId IdType="pubmed">29367883</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang W.K., Xia D. Altered intersubunit communication is the molecular basis for functional defects of pathogenic p97 mutants. J.&#xa0;Biol. Chem. 2013;288:36624&#x2013;36635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3868774</ArticleId><ArticleId IdType="pubmed">24196964</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuetz A.K., Kay L.E. A&#xa0;dynamic molecular basis for malfunction in disease mutants of p97/VCP. Elife. 2016;5</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5102582</ArticleId><ArticleId IdType="pubmed">27828775</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan M., Zheng Q., Yu Y., Ai H., Xie Y., Zeng X., Wang C., Liu L., Zhao M. Seesaw conformations of Npl4 in the human p97 complex and the inhibitory mechanism of a disulfiram derivative. Nat. Commun. 2021;12:121.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7785736</ArticleId><ArticleId IdType="pubmed">33402676</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthelme D., Jauregui R., Sauer R.T. An ALS disease mutation in Cdc48/p97 impairs 20S proteasome binding and proteolytic communication. Protein Sci. 2015;24:1521&#x2013;1527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4570545</ArticleId><ArticleId IdType="pubmed">26134898</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang W.K., Li D., Li C.C., Esser L., Dai R., Guo L., Xia D. A&#xa0;novel ATP-dependent conformation in p97 N-D1 fragment revealed by crystal structures of disease-related mutants. EMBO J. 2010;29:2217&#x2013;2229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2905243</ArticleId><ArticleId IdType="pubmed">20512113</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Z., Liu S., Xiang L., Wang Y., Liu M., Liu S., Han T., Zhou Y., Wang J., Cai L., Gao S., Ji Y. Frontotemporal dementia-related gene mutations in clinical dementia patients from a Chinese population. J.&#xa0;Hum. Genet. 2016;61:1003&#x2013;1008.</Citation><ArticleIdList><ArticleId IdType="pubmed">27439681</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe4;nzelmann P., Schindelin H. The interplay of cofactor interactions and post-translational modifications in the regulation of the AAA+ ATPase p97. Front. Mol. Biosci. 2017;4:21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5389986</ArticleId><ArticleId IdType="pubmed">28451587</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Gui L., Zhang X., Bulfer S.L., Sanghez V., Wong D.E., Lee Y.J., Lehmann L., Lee J.S., Shih P.Y., Lin H.J., Iacovino M., Weihl C.C., Arkin M.R., Wang Y. Altered cofactor regulation with disease-associated p97/VCP mutations. Proc. Natl. Acad. Sci. U. S. A. 2015;112:E1705&#x2013;E1714.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4394316</ArticleId><ArticleId IdType="pubmed">25775548</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou H.J., Wang J., Yao B., Wong S., Djakovic S., Kumar B., Rice J., Valle E., Soriano F., Menon M.K., Madriaga A., Kiss Von Soly S., Kumar A., Parlati F., Yakes F.M. Discovery of a first-in-class, potent, selective, and orally bioavailable inhibitor of the p97 AAA ATPase (CB-5083) J.&#xa0;Med. Chem. 2015;58:9480&#x2013;9497.</Citation><ArticleIdList><ArticleId IdType="pubmed">26565666</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang W.K., Odzorig T., Jin W., Xia D. Structural basis of p97 inhibition by the site-selective anticancer compound CB-5083. Mol. Pharmacol. 2019;95:286&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6355941</ArticleId><ArticleId IdType="pubmed">30591537</ArticleId></ArticleIdList></Reference><Reference><Citation>Blythe E.E., Olson K.C., Chau V., Deshaies R.J. Ubiquitin- A nd ATP-dependent unfoldase activity of P97/VCP&#x2022;NPLOC4&#x2022;UFD1L is enhanced by a mutation that causes multisystem proteinopathy. Proc. Natl. Acad. Sci. U. S. A. 2017;114:E4380&#x2013;E4388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5465906</ArticleId><ArticleId IdType="pubmed">28512218</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller J.M.M., Deinhardt K., Rosewell I., Warren G., Shima D.T. Targeted deletion of p97 (VCP/CDC48) in mouse results in early embryonic lethality. Biochem. Biophys. Res. Commun. 2007;354:459&#x2013;465.</Citation><ArticleIdList><ArticleId IdType="pubmed">17239345</ArticleId></ArticleIdList></Reference><Reference><Citation>Song C., Wang Q., Li C.C.H. ATPase activity of p97-valosin-containing protein (VCP): D2 mediates the major enzyme activity, and D1 contributes to the heat-induced activity. J.&#xa0;Biol. Chem. 2003;278:3648&#x2013;3655.</Citation><ArticleIdList><ArticleId IdType="pubmed">12446676</ArticleId></ArticleIdList></Reference><Reference><Citation>Li G., Huang C., Zhao G., Ennarz W.J.L. Interprotomer motion-transmission mechanism for the hexameric AAA ATPase p97. Proc. Natl. Acad. Sci. U. S. A. 2012;109:3737&#x2013;3741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3309748</ArticleId><ArticleId IdType="pubmed">22355145</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose R., Golosova O., Sukhomlinov D., Tiunov A., Prosperi M. Flexible design of multiple metagenomics classification pipelines with ugene. Bioinformatics. 2019;35:1963&#x2013;1965.</Citation><ArticleIdList><ArticleId IdType="pubmed">30358807</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson D.J., Le Moigne R., Djakovic S., Kumar B., Rice J., Wong S., Wang J., Yao B., Valle E., Kiss von Soly S., Madriaga A., Soriano F., Menon M.K., Wu Z.Y., Kampmann M. Targeting the AAA ATPase p97 as an approach to treat cancer through disruption of protein homeostasis. Cancer Cell. 2015;28:653&#x2013;665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4941640</ArticleId><ArticleId IdType="pubmed">26555175</ArticleId></ArticleIdList></Reference><Reference><Citation>Punjani A., Rubinstein J.L., Fleet D.J., Brubaker M.A. CryoSPARC: Algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods. 2017;14:290&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">28165473</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal P.B., Henderson R. Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy. J.&#xa0;Mol. Biol. 2003;333:721&#x2013;745.</Citation><ArticleIdList><ArticleId IdType="pubmed">14568533</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., Ferrin T.E. UCSF Chimera - a visualization system for exploratory research and analysis. J.&#xa0;Comput. Chem. 2004;25:1605&#x2013;1612.</Citation><ArticleIdList><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebschner D., Afonine P.V., Baker M.L., Bunkoczi G., Chen V.B., Croll T.I., Hintze B., Hung L.W., Jain S., McCoy A.J., Moriarty N.W., Oeffner R.D., Poon B.K., Prisant M.G., Read R.J. Macromolecular structure determination using X-rays, neutrons and electrons: Recent developments in Phenix. Acta Crystallogr. D Struct. Biol. 2019;75:861&#x2013;877.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778852</ArticleId><ArticleId IdType="pubmed">31588918</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen E.F., Goddard T.D., Huang C.C., Meng E.C., Couch G.S., Croll T.I., Morris J.H., Ferrin T.E. UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Sci. 2021;30:70&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7737788</ArticleId><ArticleId IdType="pubmed">32881101</ArticleId></ArticleIdList></Reference><Reference><Citation>Mills J.E.J. Three-dimensional hydrogen-bond geometry and probability information from a crystal survey. J.&#xa0;Comput. Aided Mol. Des. 1996;10:607&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pubmed">9007693</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>